References
- Mardis ER (2017) DNA sequencing technologies: 2006-2016. Nat Protoc 12, 213-218 https://doi.org/10.1038/nprot.2016.182
- Zhang W, Mitchell LA, Bader JS and Boeke JD (2020) Synthetic genomes. Annu Rev Biochem 89, 77-101 https://doi.org/10.1146/annurev-biochem-013118-110704
- Pickar-Oliver A and Gersbach CA (2019) The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol 20, 490-507 https://doi.org/10.1038/s41580-019-0131-5
- Sander JD and Joung JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32, 347-355 https://doi.org/10.1038/nbt.2842
- Anzalone AV, Koblan LW and Liu DR (2020) Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol 38, 824-844 https://doi.org/10.1038/s41587-020-0561-9
- Tong S, Moyo B, Lee CM, Leong K and Bao G (2019) Engineered materials for in vivo delivery of genome-editing machinery. Nat Rev Mater 4, 726-737 https://doi.org/10.1038/s41578-019-0145-9
- Ishino Y, Shinagawa H, Makino K, Amemura M and Nakata A (1987) Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme convertsion in Escherichia coli, and identification of the gene product. J Bacteriol 169, 5429-5433 https://doi.org/10.1128/jb.169.12.5429-5433.1987
- Jansen R, Embden JD, Gaastra W and Schouls LM (2002) Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol 43, 1565-1575 https://doi.org/10.1046/j.1365-2958.2002.02839.x
- Mojica FJ, Diez-Villasenor C, Garcia-Martinez J and Soria E (2005) Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol 60, 174-182 https://doi.org/10.1007/s00239-004-0046-3
- Barrangou R, Fremaux C, Deveau H et al (2007) CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 1709-1712 https://doi.org/10.1126/science.1138140
- Makarova KS, Wolf YI, Iranzo J et al (2020) Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol 18, 67-83 https://doi.org/10.1038/s41579-019-0299-x
- Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA and Charpentier E (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 https://doi.org/10.1126/science.1225829
- Mojica FJM, Diez-Villasenor C, Garcia-Martinez J and Almendros C (2009) Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology (Reading) 155, 733-740 https://doi.org/10.1099/mic.0.023960-0
- Wang H, La Russa M and Qi LS (2016) CRISPR/Cas9 in genome editing and beyond. Annu Rev Biochem 85, 227-264 https://doi.org/10.1146/annurev-biochem-060815-014607
- Ren J and Zhao Y (2017) Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9. Protein Cell 8, 634-643 https://doi.org/10.1007/s13238-017-0410-x
- Kim S, Kim D, Cho SW, Kim J and Kim JS (2014) Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 24, 1012-1019 https://doi.org/10.1101/gr.171322.113
- Hendel A, Bak RO, Clark JT et al (2015) Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol 33, 985-989 https://doi.org/10.1038/nbt.3290
- Hornung V and Latz E (2010) Intracellular DNA recognition. Nat Rev Immunol 10, 123-130 https://doi.org/10.1038/nri2690
- Geering B and Fussenegger M (2015) Synthetic immunology: modulating the human immune system. Trends Biotechnol 33, 65-79 https://doi.org/10.1016/j.tibtech.2014.10.006
- Wei SC, Duffy CR and Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8, 1069-1086 https://doi.org/10.1158/2159-8290.CD-18-0367
- Klinger M, Benjamin J, Kischel R, Stienen S and Zugmaier G (2016) Harnessing T cells to fight cancer with BiTE(R) antibody constructs--past developments and future directions. Immunol Rev 270, 193-208 https://doi.org/10.1111/imr.12393
- Guedan S, Ruella M and June CH (2019) Emerging cellular therapies for cancer. Annu Rev Immunol 37, 145-171 https://doi.org/10.1146/annurev-immunol-042718-041407
- Schuster SJ, Svoboda J, Chong EA et al (2017) Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 377, 2545-2554 https://doi.org/10.1056/NEJMoa1708566
- Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377, 2531-2544 https://doi.org/10.1056/NEJMoa1707447
- Maude SL, Laetsch TW, Buechner J et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378, 439-448 https://doi.org/10.1056/NEJMoa1709866
- Blank CU, Haining WN, Held W et al (2019) Defining 'T cell exhaustion'. Nat Rev Immunol 19, 665-674 https://doi.org/10.1038/s41577-019-0221-9
- Wherry EJ and Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15, 486-499 https://doi.org/10.1038/nri3862
- Choi BD, Yu X, Castano AP et al (2019) CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer 7, 304 https://doi.org/10.1186/s40425-019-0806-7
- Hu W, Zi Z, Jin Y et al (2019) CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunother 68, 365-377 https://doi.org/10.1007/s00262-018-2281-2
- Rupp LJ, Schumann K, Roybal KT et al (2017) CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep 7, 737 https://doi.org/10.1038/s41598-017-00462-8
- Su S, Hu B, Shao J et al (2016) CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep 6, 20070 https://doi.org/10.1038/srep20070
- Stadtmauer EA, Fraietta JA, Davis MM et al (2020) CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 https://doi.org/10.1126/science.aba7365
- Yang L, Pang Y and Moses HL (2010) TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31, 220-227 https://doi.org/10.1016/j.it.2010.04.002
- Tang N, Cheng C, Zhang X et al (2020) TGF-beta inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight 5, e133977 https://doi.org/10.1172/jci.insight.133977
- Yamada A, Arakaki R, Saito M, Kudo Y and Ishimaru N (2017) Dual role of Fas/FasL-mediated signal in peripheral immune tolerance. Front Immunol 8, 403 https://doi.org/10.3389/fimmu.2017.00403
- Ren J, Zhang X, Liu X et al (2017) A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget 8, 17002-17011 https://doi.org/10.18632/oncotarget.15218
- Riese MJ, Moon EK, Johnson BD and Albelda SM (2016) Diacylglycerol kinases (DGKs): novel targets for improving T cell activity in cancer. Front Cell Dev Biol 4, 108
- Jung IY, Kim YY, Yu HS, Lee M, Kim S and Lee J (2018) CRISPR/Cas9-mediated knockout of DGK improves antitumor activities of human T cells. Cancer Res 78, 4692-4703 https://doi.org/10.1158/0008-5472.CAN-18-0030
- Norelli M, Camisa B, Barbiera G et al (2018) Monocytederived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24, 739-748 https://doi.org/10.1038/s41591-018-0036-4
- Teachey DT, Lacey SF, Shaw PA et al (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6, 664-679 https://doi.org/10.1158/2159-8290.CD-16-0040
- Sterner RM, Sakemura R, Cox MJ et al (2019) GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 133, 697-709 https://doi.org/10.1182/blood-2018-10-881722
- Alcantara M, Tesio M, June CH and Houot R (2018) CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia 32, 2307-2315 https://doi.org/10.1038/s41375-018-0285-8
- Gomes-Silva D, Srinivasan M, Sharma S et al (2017) CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130, 285-296 https://doi.org/10.1182/blood-2017-01-761320
- Ren J, Liu X, Fang C, Jiang S, June CH and Zhao Y (2017) Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res 23, 2255-2266 https://doi.org/10.1158/1078-0432.CCR-16-1300
- Morton LT, Reijmers RM, Wouters AK et al (2020) Simultaneous deletion of endogenous TCRalphabeta for TCR gene therapy creates an improved and safe cellular therapeutic. Mol Ther 28, 64-74 https://doi.org/10.1016/j.ymthe.2019.10.001
- Maher J, Brentjens RJ, Gunset G, Riviere I and Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 20, 70-75 https://doi.org/10.1038/nbt0102-70
- Milone MC, Fish JD, Carpenito C et al (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17, 1453-1464 https://doi.org/10.1038/mt.2009.83
- Uren AG, Kool J, Berns A and van Lohuizen M (2005) Retroviral insertional mutagenesis: past, present and future. Oncogene 24, 7656-7672 https://doi.org/10.1038/sj.onc.1209043
- Niederer HA and Bangham CR (2014) Integration site and clonal expansion in human chronic retroviral infection and gene therapy. Viruses 6, 4140-4164 https://doi.org/10.3390/v6114140
- Woods NB, Muessig A, Schmidt M et al (2003) Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood 101, 1284-1289 https://doi.org/10.1182/blood-2002-07-2238
- Eyquem J, Mansilla-Soto J, Giavridis T et al (2017) Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113-117 https://doi.org/10.1038/nature21405
- Wright JF (2008) Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther 15, 840-848 https://doi.org/10.1038/gt.2008.65
- Roth TL, Puig-Saus C, Yu R et al (2018) Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 559, 405-409 https://doi.org/10.1038/s41586-018-0326-5
- Nguyen DN, Roth TL, Li PJ et al (2020) Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nat Biotechnol 38, 44-49 https://doi.org/10.1038/s41587-019-0325-6
- Roth TL, Li PJ, Blaeschke F et al (2020) Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies. Cell 181, 728-744 e721 https://doi.org/10.1016/j.cell.2020.03.039
- Tothova Z, Krill-Burger JM, Popova KD et al (2017) Multiplex CRISPR/Cas9-based genome editing in human hematopoietic stem cells models clonal hematopoiesis and myeloid neoplasia. Cell Stem Cell 21, 547-555.e8 https://doi.org/10.1016/j.stem.2017.07.015
- Wagenblast E, Azkanaz M, Smith SA et al (2019) Functional profiling of single CRISPR/Cas9-edited human long-term hematopoietic stem cells. Nat Commun 10, 4730 https://doi.org/10.1038/s41467-019-12726-0
- Cavazzana M, Antoniani C and Miccio A (2017) Gene therapy for beta-hemoglobinopathies. Mol Ther 25, 1142-1154 https://doi.org/10.1016/j.ymthe.2017.03.024
- Dever DP, Bak RO, Reinisch A et al (2016) CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature 539, 384-389 https://doi.org/10.1038/nature20134
- Wu Y, Zeng J, Roscoe BP et al (2019) Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med 25, 776-783 https://doi.org/10.1038/s41591-019-0401-y
- Zeng J, Wu Y, Ren C et al (2020) Therapeutic base editing of human hematopoietic stem cells. Nat Med 26, 535-541 https://doi.org/10.1038/s41591-020-0790-y
- Traxler EA, Yao Y, Wang YD et al (2016) A genome-editing strategy to treat beta-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med 22, 987-990 https://doi.org/10.1038/nm.4170
- Weber L, Frati G, Felix T et al (2020) Editing a gammaglobin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype. Sci Adv 6, eaay9392 https://doi.org/10.1126/sciadv.aay9392
- Hacein-Bey-Abina S, Garrigue A, Wang GP et al (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118, 3132-3142 https://doi.org/10.1172/JCI35700
- Woods NB, Bottero V, Schmidt M, von Kalle C and Verma IM (2006) Gene therapy: therapeutic gene causing lymphoma. Nature 440, 1123 https://doi.org/10.1038/4401123a
- Pavel-Dinu M, Wiebking V, Dejene BT et al (2019) Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nat Commun 10, 1634 https://doi.org/10.1038/s41467-019-09614-y
- Holt N, Wang J, Kim K et al (2010) Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28, 839-847 https://doi.org/10.1038/nbt.1663
- Shi B, Li J, Shi X et al (2017) TALEN-mediated knockout of CCR5 confers protection against infection of human immunodeficiency virus. J Acquir Immune Defic Syndr 74, 229-241 https://doi.org/10.1097/QAI.0000000000001190
- Xu L, Yang H, Gao Y et al (2017) CRISPR/Cas9-mediated CCR5 ablation in human hematopoietic stem/progenitor cells confers HIV-1 resistance in vivo. Mol Ther 25, 1782-1789 https://doi.org/10.1016/j.ymthe.2017.04.027
- Xu L, Wang J, Liu Y et al (2019) CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N Engl J Med 381, 1240-1247 https://doi.org/10.1056/NEJMoa1817426
- Hartweger H, McGuire AT, Horning M et al (2019) HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells. J Exp Med 216, 1301-1310 https://doi.org/10.1084/jem.20190287
- Moffett HF, Harms CK, Fitzpatrick KS, Tooley MR, Boon-yaratanakornkit J and Taylor JJ (2019) B cells engineered to express pathogen-specific antibodies protect against infection. Sci Immunol 4, eaax0644 https://doi.org/10.1126/sciimmunol.aax0644
- McManus MT and Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 3, 737-747 https://doi.org/10.1038/nrg908
- Jackson AL and Linsley PS (2010) Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9, 57-67 https://doi.org/10.1038/nrd3010
- Munoz DM, Cassiani PJ, Li L et al (2016) CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions. Cancer Discov 6, 900-913 https://doi.org/10.1158/2159-8290.CD-16-0178
- Tian X, Gu T, Patel S, Bode AM, Lee MH and Dong Z (2019) CRISPR/Cas9 - an evolving biological tool kit for cancer biology and oncology. NPJ Precis Oncol 3, 8 https://doi.org/10.1038/s41698-019-0080-7
- Wang T, Wei JJ, Sabatini DM and Lander ES (2014) Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 https://doi.org/10.1126/science.1246981
- Mali P, Aach J, Stranges PB et al (2013) CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 31, 833-838 https://doi.org/10.1038/nbt.2675
- Perez-Pinera P, Kocak DD, Vockley CM et al (2013) RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods 10, 973-976 https://doi.org/10.1038/nmeth.2600
- Konermann S, Brigham MD, Trevino AE et al (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583-588 https://doi.org/10.1038/nature14136
- Zalatan JG, Lee ME, Almeida R et al (2015) Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 160, 339-350 https://doi.org/10.1016/j.cell.2014.11.052
- Gilbert LA, Larson MH, Morsut L et al (2013) CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442-451 https://doi.org/10.1016/j.cell.2013.06.044
- McDade JR, Waxmonsky NC, Swanson LE and Fan M (2016) Practical considerations for using pooled lentiviral CRISPR libraries. Curr Protoc Mol Biol 115, 31.5.1-31.5.13
- Joung J, Konermann S, Gootenberg JS et al (2017) Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc 12, 828-863 https://doi.org/10.1038/nprot.2017.016
- Park RJ, Wang T, Koundakjian D et al (2017) A genomewide CRISPR screen identifies a restricted set of HIV host dependency factors. Nat Genet 49, 193-203 https://doi.org/10.1038/ng.3741
- Ait-Ammar A, Kula A, Darcis G et al (2019) Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs. Front Microbiol 10, 3060 https://doi.org/10.3389/fmicb.2019.03060
- Rathore A, Iketani S, Wang P, Jia M, Sahi V and Ho DD (2020) CRISPR-based gene knockout screens reveal deubiquitinases involved in HIV-1 latency in two Jurkat cell models. Sci Rep 10, 5350 https://doi.org/10.1038/s41598-020-62375-3
- Manganaro L, Pache L, Herrmann T et al (2014) Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in an NF-kappaB-dependent manner. J Virol 88, 7528-7540 https://doi.org/10.1128/JVI.00239-14
- Pan D, Kobayashi A, Jiang P et al (2018) A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770-775 https://doi.org/10.1126/science.aao1710
- Kadoch C and Crabtree GR (2015) Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci Adv 1, e1500447 https://doi.org/10.1126/sciadv.1500447
- Singh N, Lee YG, Shestova O et al (2020) Impaired death receptor signaling in leukemia causes antigen- independent resistance by inducing CAR T-cell dysfunction. Cancer Discov 10, 552-567 https://doi.org/10.1158/2159-8290.cd-19-0813
- Cortez JT, Montauti E, Shifrut E et al (2020) CRISPR screen in regulatory T cells reveals modulators of Foxp3. Nature 582, 416-420 https://doi.org/10.1038/s41586-020-2246-4
- Henriksson J (2019) CRISPR screening in single cells. Methods Mol Biol 1979, 395-406 https://doi.org/10.1007/978-1-4939-9240-9_23
- Klein AM, Mazutis L, Akartuna I et al (2015) Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells. Cell 161, 1187-1201 https://doi.org/10.1016/j.cell.2015.04.044
- Macosko EZ, Basu A, Satija R et al (2015) Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161, 1202-1214 https://doi.org/10.1016/j.cell.2015.05.002
- Dixit A, Parnas O, Li B et al (2016) Perturb-Seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens. Cell 167, 1853-1866. e17 https://doi.org/10.1016/j.cell.2016.11.038
- Xie S, Duan J, Li B, Zhou P and Hon GC (2017) Multiplexed engineering and analysis of combinatorial enhancer activity in single cells. Mol Cell 66, 285-299.e5 https://doi.org/10.1016/j.molcel.2017.03.007
- Jaitin DA, Weiner A, Yofe I et al (2016) Dissecting immune circuits by linking CRISPR-pooled screens with single-cell RNA-Seq. Cell 167, 1883-1896.e15 https://doi.org/10.1016/j.cell.2016.11.039
- Datlinger P, Rendeiro AF, Schmidl C et al (2017) Pooled CRISPR screening with single-cell transcriptome readout. Nat Methods 14, 297-301 https://doi.org/10.1038/nmeth.4177
- Adamson B, Norman TM, Jost M et al (2016) A multiplexed single-cell CRISPR screening platform enables systematic dissection of the unfolded protein response. Cell 167, 1867-1882.e21 https://doi.org/10.1016/j.cell.2016.11.048
- McFaline-Figueroa JL, Hill AJ, Qiu X, Jackson D, Shendure J and Trapnell C (2019) A pooled single-cell genetic screen identifies regulatory checkpoints in the continuum of the epithelial-to-mesenchymal transition. Nat Genet 51, 1389-1398 https://doi.org/10.1038/s41588-019-0489-5
- Chopin M, Lun AT, Zhan Y et al (2019) Transcription factor PU.1 promotes conventional dendritic cell identity and function via induction of transcriptional regulator DC-SCRIPT. Immunity 50, 77-90.e5 https://doi.org/10.1016/j.immuni.2018.11.010
- Haapaniemi E, Botla S, Persson J, Schmierer B and Taipale J (2018) CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med 24, 927-930 https://doi.org/10.1038/s41591-018-0049-z
- Cullot G, Boutin J, Toutain J et al (2019) CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations. Nat Commun 10, 1136 https://doi.org/10.1038/s41467-019-09006-2
- Webber BR, Lonetree CL, Kluesner MG et al (2019) Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nature Communications 10, 5222 https://doi.org/10.1038/s41467-019-13007-6
- Strecker J, Ladha A, Gardner Z et al (2019) RNA-guided DNA insertion with CRISPR-associated transposases. Science 365, 48-53 https://doi.org/10.1126/science.aax9181
- Klompe SE, Vo PLH, Halpin-Healy TS and Sternberg SH (2019) Transposon-encoded CRISPR-Cas systems direct RNA-guided DNA integration. Nature 571, 219-225 https://doi.org/10.1038/s41586-019-1323-z